All In Biotech

Drug Trial Radar · NCT07790861

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).

Conditions

  • Obesity
  • Overweight

Interventions

  • OrforglipronDrug

    Administered orally.

  • PlaceboDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change From Baseline in Body WeightTime frame: Baseline, Week 48

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • Zhujiang Hospital

    Guangzhou, China

  • The first Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, China

  • The Second People's Hospital of Hefei

    Hefei, China

  • Jinan Central Hospital

    Jinan, China

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang Shi, China

  • Jiangxi Provincial People's Hospital

    Nanchang, China

  • Nanjing First Hospital

    Nanjing, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Shanghai Sixth People's Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.